FGFR1 and WT1 are markers of human prostate cancer progression. - Wikidata - awgldk - TriplyDB

FGFR1 and WT1 are markers of human prostate cancer progression.

FGFR1 and WT1 are markers of human prostate cancer progression.

http://www.wikidata.org/entity/Q33265116

about

LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials FGFR1 is essential for prostate cancer progression and metastasis Prostate cancer invasion and metastasis: insights from mining genomic data.Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer The transforming acidic coiled coil (TACC1) protein modulates the transcriptional activity of the nuclear receptors TR and RAR.Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.A structure-guided approach to creating covalent FGFR inhibitors Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression.Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.Fibroblast growth factors and their receptors in cancer.The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer.

P2860

Q21202034-6EBA825F-9C88-4D5D-AA92-9AFD08F019DB Q26863333-0D8FBBC2-AEAB-4F29-9EA1-B2392CA3F190 Q27026836-F79CEEE2-C401-40D8-84DD-DECFF8D3D78A Q28288755-52846876-4DFC-4D59-BF8B-3D4BDAF511E0 Q30656758-57945DAF-3C59-4353-A84C-A7D6F23EE23F Q33352317-AB113D6D-4478-4430-88BA-EAB3E992E173 Q33524554-64D8C374-0162-4EE8-9381-04C6A7A4B8B1 Q33567270-27321CA9-27E5-4866-B39C-F2ED814448BF Q34061522-661C2468-81C8-44BA-8852-1692CD9B6AF2 Q35830052-D8600BF3-E522-4786-8665-615EE2FDAD8D Q36660546-2A5F6FA0-1717-48DA-A043-60BE4C90C593 Q37895306-0C9DEE6E-BA9F-416B-9471-962633407351 Q38318725-03B332C7-53C0-4936-96F4-4FCE651A1F78 Q38407976-EF64482B-A20D-40F7-BA42-BAEFB6D3631B Q39568871-B2563C96-662A-4C45-B829-16699850097F Q54316753-6B9CFC39-7222-46F3-978E-D995BC9F3668 Q54976511-8AB70F53-1103-4667-B50C-18CC47B09683

P2860

FGFR1 and WT1 are markers of human prostate cancer progression.

http://www.wikidata.org/entity/Q33265116

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

FGFR1 and WT1 are markers of human prostate cancer progression.

@ast

FGFR1 and WT1 are markers of human prostate cancer progression.

@en

type

label

FGFR1 and WT1 are markers of human prostate cancer progression.

@ast

FGFR1 and WT1 are markers of human prostate cancer progression.

@en

prefLabel

FGFR1 and WT1 are markers of human prostate cancer progression.

@ast

FGFR1 and WT1 are markers of human prostate cancer progression.

@en

P1433

Q33265116-B1C61D7D-4C6B-4E57-BBBE-6255A0676FBC

P1476

Q33265116-838AF6F5-7115-4ED1-81BC-AE4235065DEB

P2093

Q33265116-3338D932-2808-452E-9AAF-622FBFAAF7C4

Q33265116-4F84264E-A3D3-4231-810F-88CBBE148A33

Q33265116-5591BBEF-464C-477E-955F-AAE604C822E3

Q33265116-6CC2502B-B1CD-4BD1-9561-D77B3D6E897A

Q33265116-71625B87-690C-489B-B510-A7316B86E949

Q33265116-7F1217A5-0213-4A7E-BE3E-973CBF974229

Q33265116-8CB8ED8E-65D8-4164-BF0D-084BFEE6DAB4

Q33265116-96706DEC-BBF3-4662-9A26-F2CA2EDB58A5

Q33265116-C18D00A4-D7A0-455C-AF1B-582186E0693F

Q33265116-DE29F544-C26A-4B09-AAAD-F628C143522A

P2860

Q33265116-08AFC10F-863A-436F-B2ED-4A4C1559ADB4

Q33265116-09D6A28D-5ABF-4BA2-8048-EE590BCD1159

Q33265116-14830FDD-228C-44C8-8833-02A602D90101

Q33265116-174D9556-3998-4CB6-97AE-79BC35699A25

Q33265116-2C0770D3-121F-468D-8BA2-B5FE46A6E08F

Q33265116-2C74B3D3-2F20-4246-9E49-3E3159306FDD

Q33265116-2FD4A63B-8CCC-4F25-A617-BA915EB0E08E

Q33265116-39501B18-04D5-4D7D-9646-1233D81A7A6A

Q33265116-43F0D9AB-F78C-48BC-8418-200946722762

Q33265116-45F29114-7AB9-4620-A49F-A9B845196EAA

P2888

Q33265116-CB25DCA7-D90B-4A30-BBF1-617A563D05C8

P304

Q33265116-D038FF2C-1E09-48F4-8206-C9DC81DCE7A9

P31

Q33265116-D19B153F-7791-4669-90BB-EB60CD5C1833

P356

Q33265116-AD6069A1-8E35-48D5-B0B2-1C2C7CBE6A71

P407

Q33265116-258C46E3-87A8-4AE1-A18D-95819DFE1381

P478

Q33265116-434177E1-2C92-49F6-9E80-E0C44CB79131

P577

Q33265116-FE92ADDE-F4C1-4DDB-8F18-DF8F9DA0BFE0

P5875

Q33265116-782EE8D5-C03C-404D-A6F3-54869D43B45E

P6179

Q33265116-68F8207E-6CB3-49A6-AB64-8C6F31FF3B57

P698

Q33265116-A50DA332-E982-4599-83DD-AE4546881E68

P932

Q33265116-9F78E341-273A-45B8-AF5A-5D45E300DE0D

P356

1471-2407-6-272

P1433

P1476

FGFR1 and WT1 are markers of human prostate cancer progression.

@en

P2093

Catherine Nguyen

http://www.w3.org/2001/XMLSchema#string

Daniel Birnbaum

http://www.w3.org/2001/XMLSchema#string

Elizabeth Devilard

http://www.w3.org/2001/XMLSchema#string

Franck Bladou

http://www.w3.org/2001/XMLSchema#string

François Bertucci

http://www.w3.org/2001/XMLSchema#string

Gilles Karsenty

http://www.w3.org/2001/XMLSchema#string

Gwenaëlle Gravis

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Dalès

http://www.w3.org/2001/XMLSchema#string

Luc Xerri

http://www.w3.org/2001/XMLSchema#string

Olivier Ramuz

http://www.w3.org/2001/XMLSchema#string

P2860

The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor

Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators

AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression

D-TACC: a novel centrosomal protein required for normal spindle function in the early Drosophila embryo

Cluster analysis and display of genome-wide expression patterns

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

The development of androgen-independent prostate cancer

Tissue microarrays for high-throughput molecular profiling of tumor specimens

The role of Wilms' tumor genes.

The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines.

P2888

1471-2407-6-272

P304

272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-6-272

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6660424

http://www.w3.org/2001/XMLSchema#string

P6179

1020312325

http://www.w3.org/2001/XMLSchema#string

P698

17137506

http://www.w3.org/2001/XMLSchema#string

P932

1698935

http://www.w3.org/2001/XMLSchema#string